Table 4.

Effect of Treatment on Risk of Progression to Advanced AMD^*

	Participants in AMD Categories 2, 3, and 4 (n = 3609)		Participants in AMD Categories 3 and 4 (n = 2556)
Treatment	OR (99% CI)	PValue	OR (99% CI)	PValue
Antioxidants vs no antioxidants	0.87 (0.70–1.09)	.12	0.83 (0.66–1.06)	.05
Zinc vs no zinc	0.82 (0.66–1.03)	.02	0.79 (0.62–0.99)	.009
Antioxidants vs placebo	0.80 (0.59–1.09)	.07	0.76 (0.55–1.05)	.03
Adjusted	0.77 (0.56–1.05)	.03†	0.76 (0.54–1.05)	.03†
Zinc vs placebo	0.75 (0.55–1.03)	.02	0.71 (0.52–0.99)	.008
Adjusted	0.71 (0.51–0.98)	.005†	0.70 (0.50–0.97)	.005†
Antioxidants + zinc vs placebo	0.72 (0.52–0.98)	.007	0.66 (0.47–0.91)	.001
Adjusted	0.68 (0.49–0.93)	.002†	0.66 (0.47–0.93)	.001†
Total No. of participants with events	803		775

^*Advanced age-related macular degeneration (AMD) indicates photocoagulation or other treatment for choroidal neovascularization, central geographic atrophy, nondrusenoid retinal pigment epithelial detachment, serous or hemorrhagic retinal detachment, hemorrhage under the retina or pigment epithelium, or subretinal fibrosis; OR, odds ratio; and CI, confidence interval. Analysis by repeated-measures logistic regression, unadjusted. P≤.01 is considered statistically significant.

^†Adjusted for age, sex, race, AMD category, and baseline smoking status.